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ABSTRACT
Objectives: Tissue plasminogen activator (tPA) is a key enzyme for fibrin degradation and the proteolytic defense against 
formation of the thrombotic endothelial deposits. tPA is involved in carcinogenesis but its exact role in tumor biology is not 
very well understood and a prognostic value of tPA remains ambiguous in different cancers. The aim of the study was to assess 
the prognostic value of plasma tPA in patients with epithelial ovarian cancer (EOC) in the course of the first line chemotherapy. 
Material and methods: the study covered 60 patients with EOC who underwent the 1st line chemotherapy. Plasma tPA 
was assessed at onset, after 3 and 6 cycles of chemotherapy. The groups were stratified according to tPA level at onset of 
chemotherapy (low tPA group < 6.5 mg/L, N = 37 and high tPA group > 6.5 mg/L, N = 23). Survival analysis was repeated 
for the cut-off of tPA level at 6.5 mg/L and 5.1 mg/L after 3 and 6 cycles. 
Results: Only subjects with tPA > 6.5 mg/L at onset of chemotherapy had a significantly lower probability of a 5-year 
survival (34.8% vs. 72.7%, P < 0.006) and lower chance for disease free survival within 5 years (39.3% vs. 72.7%, P < 0.014). 
tPA < 6.5 mg/L plasma level evaluated at onset of chemotherapy was an independent marker of better overall survival 
(RR = 0.44, 95%CI = 0.19–0.98) but not disease-free survival.
Conclusions: Plasma tPA may serve as a marker of survival if assessed at onset of the first line chemotherapy in patients 
with ovarian cancer. 
Key words: tissue plasminogen activator; tPA; epithelial ovarian cancer; chemotherapy;  overall survival; disease free survival
Ginekologia Polska 2019; 90, 5: 235–241
INTRODUCTION
Hemostatic markers are predictors for both thrombo-
sis and hemorrhage. Malignancy enhances the process of 
fibrin formation and degradation. Local blood clotting is 
a process strictly associated with cancer — both platelet 
aggregates and fibrin depositions are found in tumors dur-
ing histopathological investigations.  It is known that hyper-
coagulability promotes thromboembolic events in cancer 
with frequency much higher than in benign conditions [1]. 
Cancer associated thrombosis (CAT) can be linked to onco-
genic lesions that account for the onset and progression 
of malignant disease [2]. Abnormal results of hemeostatic 
laboratory tests change with cancer progression, which con-
firms the impact of tumor on blood clotting [3]. As the con-
nection between fibrinolysis and metastasis is established, 
different fibrinolytic biomarkers are investigated with the 
aim of foreseeing a prognosis. Two types of plasminogen 
activators are found in plasminogen activator system — tis-
sue type plasminogen activator (tPA) and urokinase type 
plasminogen activator (uPA). They both can turn inactive 
plasminogen to active plasmin. tPA is present in both normal 
and malignant tissues and is mainly involved in the conver-
sion of plasminogen to plasmin during blood clot dissolu-
tion, while uPA, which is mainly associated with malignancy, 
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plays a role in proteolysis during cell migration and tissue 
remodeling [4]. Cell migration is increased by promotion of 
tPA and uPA mediated proteolytic cleavage of plasminogen 
to generate plasmin. That subsequently affects breakdown 
of basement membrane to facilitate cell migration [5, 6]. 
tPA is considered a key enzyme in fibrin degradation 
and is crucial for the proteolytic defense against formation 
of the thrombotic endothelial deposits. However, tPA 
is also produced by epithelial cells, fibroblasts, and 
macrophages. The role of tPA in tumor biology is not well 
understood. In breast cancer contradictory results have 
been reported: high tumor tissue content of tPA was 
observed to be associated with good prognosis, whereas 
high content of the tPA:PAI-1 complex was associated with 
shorter disease-free survival (DFS) and overall survival (OS) 
[7]. In ovarian cancer large amounts of fibrin are deposited 
within and around ovarian tumors secondary to the release 
of tissue factor from tumor cells and macrophages. Fibrin 
may enhance tumor cell adhesion to endothelial and 
mesothelial surfaces. The fibrin deposition leads to the 
activation of plasminogen mediated by tPA which results 
in degradation of matrix by plasmin [8]. As an evidence 
of the above process, fibrin degradation products are 
detectable in high concentrations in peripheral blood 
and ascitic fluid [9]. Experimental data on mechanism of 
action of tPA encouraged scientist to evaluate its role as 
a prognostic factor in EOC. There are some studies which 
showed that a high expression of tPA in tumor tissue is 
a negative predictor of survival [10, 11]. However, very little 
is known about possible predictive meaning of plasma tPA 
especially at various stages of EOC treatment [12].
Objectives
The aim of our study was to investigate the prognostic 
significance of plasma tPA in patients with epithelial 
ovarian cancer who underwent the first line chemotherapy.
MATERIALS AND METHODS
Ethics statement
The study was conducted under the approval of the local 
Bioethics Committee at Medical University of Warsaw. All 
subjects have provided written informed consent.
Patients and samples
The study was carried out between 2011 and 
2018. 60 patients with a diagnosis of epithelial ovarian cancer 
(EOC), who had previously undergone surgery, were 
enrolled into the study at the onset of the first line adjuvant 
chemotherapy.  Chemotherapy regimen included 6 cycles of 
intravenous paclitaxel and carboplatin. Blood samples were 
taken from the patients at the onset of chemotherapy, and 
again after 3 and 6 cycles of chemotherapy. tPA, fibrinogen, 
D-dimer and antithrombin III (AT III) were assessed in blood 
plasma. Besides prothrombin time (PT), activated partial 
thromboplastin time (APTT), and international normalized 
ratio (INR) test was performed.  The IMUBIND® tPA ELISA 
(Sekisui Diagnostics, LLC, USA) test was used for the 
quantitative measurement of tPA in plasma. 
Response to chemotherapy was assessed according to 
RECIST 1.1 criteria [13]. OS was defined as time from the 
start of treatment until death from any cause and DFS was 
defined as time from the start of treatment until disease 
progression or death (according to Food and Drug Admin-
istration guidance) [14]. The clinicopathological data were 
obtained from medical records.
Two groups of patients were identified according to tPA 
level at the onset of chemotherapy: tPA < 6.5 mg/L group 
and tPA > 6.5 mg/L group. The choice of the tPA cut-off 
level was based on analysis of tPA level distribution. The 
mean follow-up time from the initial treatment which in-
cluded surgery was 57.0 ± 22.9 months (2.6 to 87.6 months).
Statistical analysis
The results were presented as mean ± standard deviation 
(SD). Significant statistical differences between groups were 
assessed applying the chi-square test, exact Fisher test or 
Student’s t test. The Kaplan–Meier method was employed 
to plot survival curves, and differences in survival were 
compared using the log-rank test. The Cox regression model 
was used to ascertain the value of independent prognosis 
for patients with epithelial ovarian cancer. P < 0.05 was 
considered statistically significant.
RESULTS
The low tPA (< 6.5 mg/L) group consisted of 37 patients 
and the high tPA group (> 6.5 ng/mL) was represented by 
23 subjects. The clinicopathological characteristic of the 
groups is presented in Table 1.
No differences between the groups were observed re-
garding patient age, tumor stage and grade, and histologi-
cal type of malignancy. Only the rate of overweight/obese 
patients (BMI > 25 kg/m2/) was significantly higher in the 
high tPA group (P = 0.006). The results of the first-line chemo-
therapy are presented in Table 2.  
No differences in response to chemotherapy were ob-
served in the low and high tPA group regardless of the way 
the response was stratified (complete remission — partial 
remission — stabilization — progression or any response 
vs. no response). 
We evaluated tPA plasma level in both groups after 3 and 
6 cycles of chemotherapy and found that tPA concentration 
was significantly higher in the high tPA group throughout 
the whole 1st line of chemotherapy. PT and INR were other 
coagulation parameters significantly elevated from the on-
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set till the end of chemotherapy when compared between 
the low and high tPA group (Tab. 3).  
Survival analyses
We plotted Kaplan-Meier curves (Fig. 1) to analyze 
OS and DFS according to tPA level at different stages of 
chemotherapy. 
Subjects with tPA > 6.5 mg/L at the onset of 
chemotherapy had a significantly lower probability of 
a 5-year survival (34.8% vs. 72.7%, P < 0.006) and chance 
for disease free survival within 5 years was significantly 
lower in this group (39.3% vs. 72.7%, P < 0.014), (Fig. 1). We 
repeated the analysis after 3 and 6 cycles of chemotherapy 
for the cut-off of tPA level at 6.5 mg/L and 5.1 mg/L (the 
level of 5.1 mg/L corresponded the best with the results 
presented in Table 3). However, we found no significant 
differences in DFS and OS in all those groups after 3 and 
6 cycles of chemotherapy (Fig. 2 and 3).
Univariate analysis showed that a high tPA plasma level 
at the onset of chemotherapy, advanced tumor stage, tumor 
grade 2 or 3 and residual disease were associated with worse 
OS and DFS. BMI > 25 kg/m2 was only related to shorter 
DFS (Tab. 4). 
Multivariate analysis revealed that tPA plasma level at 
onset of chemotherapy was an independent marker of OS 
but not DFS (Tab. 5). Tumor stage and grade were also in-
dependent predictors of OS.
DISCUSSION
The pathogenesis of hemostatic disorders in cancer is 
complex and reflects an interaction of coagulation  and 
fibrinolytic system, vascular endothelium, leukocytes, and 
platelets. Circulating biomarkers of hemostasis have been 
extensively studied to predict cancer outcomes along with 
predicting the thrombotic risk. Plasminogen activators re-
leased from cancer cells lead to degradation of basement 
membrane proteins and extracellular matrix and facilitate 
cancer cell invasion into surrounding tissues and blood 
stream. It has been shown that tPA plays a major role in inva-
sion in case of different types of highly aggressive tumors 
such as melanoma, glioblastoma, pancreatic, breast and 
endometrial cancer [15–19]. Majority of authors investigated 
Table 1. Clinicopathological characteristic of the low and high tPA 
group. Values are mean +/-SD or present a number [%] of cases in 
groups. Student’s t test or exact Fisher test were applied, respectively
Low tPA group 
(< 6.5 mg/L)
N = 37
High tPA group 
(> 6.5 mg/L)
N = 23
P
Age [years] 53.4 ± 10.6 59.1 ± 12.5 0.06
BMI =< 25 [kg/m2] 11 (29.7%) 16 (69.6%) 0.006
Histological type n [%]
•	 Serous
•	 Endometrioid
•	 Clear cell 
•	 Mucinous 
15 (40.6%)
12 (32.4%)
8 (21.6%)
2 (5.4%)
14 (73.7%)
1 (5.2%)
4 (21.1%)
0 (0%)
0.06
Stage n (%)
I
II
III
IV
12 (32.4%)
4 (10.8%)
21 (56.8%)
0 (0%)
6 (26.1%)
1 (4.3%)
15 (65.2%)
1 (4.4%)
0.44
Grade n (%)
1
2
3
9 (24.3%)
17 (46.0 %)
11 (29.7%)
6 (26.1%)
4 (17.4%)
13 (56.5%)
0.06
Early cancer (FIGO I-II)
Advanced cancer 
(FIGO III-IV)
16 (43.2%)
21 (56.8%)
7 (30.4%)
16 (69.6%)
0.47
Table 2. Correlation between tPA serum level and the clinical results 
of the first line chemotherapy. Values are mean +/- SD or present 
a number [%] of cases in groups. Student’s t test or exact Fisher test 
were applied, respectively
Low tPA group 
(< 6.5 mg/L)
N = 37
High tPA group 
(> 6.5 mg/L)
N = 23
P
Response to 
treatment
•	 Complete 
remission
•	 Partial remission
•	 Stabilization
•	 Progression 
Any response 
vs. progression
33 (89.2%)
2 (5.4%)
0 (0%)
2 (5.4%)
35 (0.94.6%)
2 (0.05.4%)
17 (73.9%
1 (4.4%)
1 (4.4%)
4 (17.3%)
19 (82.6%)
4 (17.4%)
0.25
0.29
Table 3. The results of coagulation tests in the low and high tPA 
group at the onset, after 3 and 6 cycles of chemotherapy. Values 
present mean +/- SD. Student’s t test
Low tPA group 
(< 6.5 mg/L)
N = 37
High tPA group 
(> 6.5 mg/L)
N = 37
P
At onset of chemotherapy
PT [s]
APTT [s]
D-dimer [mg/L]
Fibrinogen [g/L]
11 .32 ± 0 .75
28 .26 ± 2 .93
2 .08 ± 4 .66
3 .52 ± 0 .76
11 .93 ± 1 .24
28 .67 ± 4 .04
2 .80 ± 2 .28
3 .64 ± 0 .84
0 .02
0 .65
0 .49
0 .56
After 3 cycles of chemotherapy
tPA [mg/L]
PT [s]
APTT [s]
D-dimer [mg/L]
Fibrinogen [g/L]
3.57 ± 1.08
10.94 ± 0.63
27.92 ± 2.97
0.67 ± 0.47
3.51 ± 0.59
9.83 ± 7.75
11.44 ± 0.85
28.01 ± 3.31
1.27 ± 1.45
3.66 ± 0.73
0.0007
0.03
0.92
0.06
0.47
After 6 cycles of chemotherapy
tPA [mg/L]
PT [s]
APTT [s]
D-dimer [mg/L]
Fibrinogen [g/L]
4.13 ± 1.64
11.01 ± 0.70
27.30 ± 2.80
1.49 ± 3.73
3.22 ± 0.64
7.45 ± 4.35
11.48 ± 0.86
27.88 ± 3.21
2.17 ± 3.61
3.46 ± 0.62
0.002
0.06
0.52
0.56
0.24
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tissue tPA levels and obtained data came from the removed 
tumor at the time of surgery [15–17, 19]. In our opinion this 
approach has got a weakness: tumor state in vivo is much 
more complex than in cell culture. Neoplastic and nonneo-
plastic cells manifest migratory and invasive properties, 
linked to the cancer cell-induced process of tissue recon-
struction. Expression of the plasminogen activation system 
differs between various tumors originating from the same 
tissue or from the same organ, depending on the extent of 
their histological differentiation [13]. In neoplastic cells the 
degradation of the extracellular matrix proteins is facilitated 
by excessive expression of t-PA. In many forms of carcinoma 
increased expression of fibrinolytic biomarkers is associated 
with significantly shorter survival. In acute nonlymphocytic 
leukemias, poor outcome correlates with high t-PA levels 
[14]. In the study by Chernicky et al. on breast cancer, low 
expression of tissue tPA correlated with better prognosis 
and longer DFS [15].
We decided to investigate the prognostic significance 
of plasma tPA in patients with epithelial ovarian cancer 
who underwent the first line chemotherapy. We found only 
one study which investigated prognostic value of plasma 
levels of selected fibrinolytic parameters in ovarian can-
cer [12]. Ho et al. showed that blood tPA did not differ 
in patients with malignant tumors, benign gynecological 
diseases and healthy controls. The expression of tissue 
tPA was significantly lower inside the tumor compared 
with adjacent ovarian tissue but there was no significant 
correlation between plasma and tissue concentration of 
tPA. In our study plasma concentration of tPA < 6.5 mg/L 
Figure 1. Kaplan-Meier analysis of disease-free survival (DFS) and overall survival (OS) according to tPA level at onset of chemotherapy. A. — DFS, 
6.5 mg/L < tPA < 6.5 mg/L; B. — OS, 6.5 mg/L < tPA < 6.5 mg/L, Log rank test
Figure 2. Kaplan-Meier analysis of disease-free survival (DFS) and overall survival (OS) according to tPA level after 3 cycles of chemotherapy. A. DFS, 5.1 
mg/L < tPA <5.1 mg/L; B. — OS, 5.1 mg/L < tPA < 5.1 mg/L; C. — DFS, 6.5 mg/L < tPA < 6.5 mg/L; D. — OS, 6.5 mg/L < tPA < 6.5 mg/L; Log rank test
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at the onset of chemotherapy was associated with longer 
OS and DFS. Our decision to determine plasma tPA just 
before the beginning of chemotherapy was based on the 
fact that this is the time when discussion with a patient 
Figure 3. Kaplan-Meier analysis of disease-free survival (DFS) and overall survival (OS) according to tPA level after 6 cycles of chemotherapy. A. — DFS, 
5.1 mg/L < tPA < 5.1 mg/L; B. — OS, 5.1 mg/L < tPA <5.1 mg/L; C. — DFS, 6.5 mg/L < tPA < 6.5mg/L; D. — OS, 6.5 mg/L < tPA < 6.5 mg/L; Log rank test
Table 4. Univariate analysis of factors associated with OS and DFS. The Cox regression model. RR presents relative risk of death or 
relapse/progression, respectively
Variable
OS DFS
RR 95% CI P RR 95% CI P
tPA < 6.5 mg/L vs. > 6.5 mg/L 0.34 0.15–0.73 0.006 0.35 0.15–0.80 0.01
FIGO I-II vs. III–IV 0.09 0.02–0.36 0.0009 0.12 0.03–0.50 0.005
Grade 1 vs. 2–3 0.29 0.13–0.65 0.003 0.43 0.19–0.98 0.04
Residual disease 0.25 0.11–0.54 0.0005 0.20 0.09–0.47 0.0002
BMI < 25 kg/m2 vs. ≥ 25 kg/m2 0.55 0.25–1.20 0.13 0.36 0.15–0.84 0.02
Serous vs. non-serous tumor 0.61 0.25–1.46 0.27 0.70 0.29–1.71 0.43
Age ≤ 60 years vs. > 60 years 0.38 0.50–2.15 0.93 0.94 0.40–2.20 0.88
Table 5. Multivariate Cox regression analysis of factors associated with OS and DFS. RR presents relative risk of death or relapse/progression, 
respectively
Variable
OS DFS
RR 95% CI P RR 95% CI P
Low vs. high tPA 0.44 0.19–0.98 0.044 0.59 0.25-1.40 0.23
FIGO 1–2 vs. 3–4 0.12 0.03–0.55 0.006 0.26 0.05-1.27 0.09
Grade 1 vs. 2–3 0.33 0.15–0.76 0.009 0.57 0.24-1.34 0.20
Residual disease 0.52 0.23–1.18 0.117 0.41 0.16-1.02 0.06
BMI < 25 vs. ≥ 25 0.61 0.25–1.48 0.28
about prognosis takes place, adjuvant therapy is outlined 
and the need for reliable prognostic factors is indisputable. 
For the same reason we decided to repeat our analysis after 
3 and 6 cycles of chemotherapy. We chose two cut-off levels 
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of plasma tPA: 6.5 mg/L and 5.1 mg/L. There were no sig-
nificant differences neither in OS nor in DFS in all analyzed 
settings. These results have proven the clinical prognostic 
usefulness of plasma tPA determination only at the onset 
of the first line chemotherapy, not later. There is no data in 
the literature that could be compared with our findings. The 
above-mentioned Ho et al. didn’t give any information on 
the time of collecting plasma samples, whether it was in 
any way connected with surgery or chemotherapy [12]. We 
also performed Cox regression analysis which proved that 
plasma tPA level of 6.5 mg/L at the onset of chemotherapy 
was a marker of short OS and DFS in univariate analysis 
and an independent marker of poor OS in multivariate 
analysis. This result makes tPA a good candidate for a clini-
cal biomarker of EOC prognosis. 
It is important to underline that our low and high plasma 
tPA groups were homogenic in terms of patients age, tumor 
stage, grade and histological type of malignancy as well as 
response to chemotherapy. Only the rate of overweight 
and obese patients was significantly higher in the high 
plasma tPA group. The impact of BMI on hemostatic mark-
ers has been widely discussed, although data concerning 
tPA is conflicting [20–22]. Smith et al. found that plasma tPA 
concentration positively correlated with triglyceride levels 
and BMI and negatively with HDL cholesterol level whereas 
Morgan et al. didn’t confirm that relationship [23, 24]. Our 
univariate analysis revealed that BMI > 25 kg/m2 didn’t in-
crease the risk of death but was associated with shorter 
DFS. In multivariate analysis BMI was not an independent 
factor of OS and DFS. 
We also specifically looked at the clotting global tests 
as their availability in clinical settings is widely known [11, 
25–27]. Mean PT was statistically longer in the high tPA 
group but didn’t exceed the upper reference value at the 
onset and after 3 and 6 cycles of chemotherapy. Our findings 
were consistent with the study by Tas et al. where prolonged 
PT was associated with poorer OS (P = 0.03) and progression 
free survival (PFS) (P = 0.04) [28].
Independent prognostic value of the tumor stage, tumor 
grade and residual disease associated with poor OS in our 
study is consistent with many other studies regarding EOC 
[7, 17, 29]. Lack of significance in DFS comparison may reflect 
the limitation of our study design which is the sample size. 
CONCLUSIONS
Plasma tPA is an independent marker of survival if 
assessed at the onset of the first line chemotherapy in 
patients with ovarian cancer.
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